



156-158 Buckingham Palace Road, London, SW1W 9TR
Tel: +44 (0)20 7259 8482 – Fax: +44 (0)20 7259 8480

Beata Brozek joins management teams at InterPharm Investments Ltd and InterAlia srl

13th September 2011. InterPharm Investments Ltd, a London-based 'search and development' company focussing on medical foods and dietary supplements, has appointed Beata Brozek to its Executive Committee.

Beata Brozek brings to InterPharm her experience in marketing and business management in the OTC and consumer healthcare sectors. She worked as Marketing Director, Country Manager and in other commercial roles in leading international pharmaceutical companies including Roche, Pharmacia Upjohn, Giuliani and IBSA in Poland, Central and Eastern Europe, Italy and Switzerland. Beata co-founded Marbea International, a brokerage and consulting firm, where she has built a successful business managing new market entries at both local and regional level through licensing and distribution agreements in Rx, OTC and consumer healthcare. Beata, who is Polish, is an MBA level graduate MBA of the Warsaw School of Economics (SGH).

In a parallel move, InterPharm's affiliate company in Italy, InterAlia srl, expanded its Board of Directors. Elaine Evans and Beata Brozek from InterPharm join Claudio Antico, InterAlia's CEO, and Sergio Cecchinato. Sergio has been a mainstay of InterAlia's team since it was incorporated. Sergio Cecchinato spent 25 years as a General Administrator and as a Director in various companies, mainly in the pharma sector (for example Fidia Farmaceutici SpA and Istoria srl). In 1998 Sergio set up an independent agency providing services to companies on corporate, fiscal and administrative matters. Claudio Antico is building the company's management team as the company gears up to its second product launch, due later this year.

InterAlia provides a first channel to market for new products developed by InterPharm as well as for in-licensed products. InterPharm is building a portfolio of patented medical foods, dietary supplements and medical devices for management of medical conditions identified by specialist physicians or dentists. Through co-financing, InterPharm supports the development of such products in exchange for rights to patents in specified territories.

For further information, contact InterPharm's CEO Elaine Evans at:

eevans@interpharminvestments.com

About InterPharm Investments Ltd www.interpharminvestments.com

InterPharm Investments Ltd is a UK-based 'search and development' company building a pipeline of patent-protected products which can be developed and commercialised as medical foods, dietary supplements or medical devices.

About InterAlia srl www.interalia.it

InterAlia srl is an Italian affiliate of InterPharm. InterAlia's first product is Hali-Z, a patented zinc-based lozenge formulation for enhancement of oral hygiene. InterAlia is presently building a portfolio of products in oral healthcare, promoted nationally at pharmacy level and to dentists. InterAlia will diversify its therapeutic focus in line with InterPharm's pipeline.